Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | USP5 | P45974 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177501 | 0.88 | ALDH1A1 (0.70) | ALDH1A1KDM4ECYP2D6CYP2C19EPHX2 | |
| SCHEMBL28485534 | 0.87 | LMNA (0.69) | SMN1; SMN2ALDH1A1KDM4ELMNAEPHX2 | |
| SCHEMBL22033972 | 0.85 | MEN1 (0.72) | SMN1; SMN2ALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL20456436 | 0.82 | MEN1 (0.55) | ALDH1A1KDM4ECYP2D6CYP2C19EPHX2 | |
| SCHEMBL2171815 | 0.82 | EPHX2 (0.61) | SMN1; SMN2EPHX2KMT2AMEN1LIPE | |
| SCHEMBL31467609 | 0.80 | MEN1 (0.47) | SMN1; SMN2ALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL165947 | 0.79 | ALDH1A1 (0.67) | SMN1; SMN2ALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL1676915 | 0.79 | EPHX2 (0.62) | SMN1; SMN2ALDH1A1LMNAEPHX2KMT2A | |
| SCHEMBL19823117 | 0.79 | MEN1 (0.54) | ALDH1A1KDM4ECYP2D6CYP2C19LMNA | |
| SCHEMBL17014229 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4ECYP2D6CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344511-B2 | Compounds and methods of promoting myelination | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-05-31 | — | — | US | disclosed |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY | 2019-09-05 | — | — | US | disclosed |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018022904-A2 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-02-01 | — | — | WO | disclosed |
| US-9856233-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232444-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | SMN1; SMN2 4761/4885ALDH1A1 4595/4885KDM4E 2086/4885 |
| US-11344511-B2 | Compounds and methods of promoting myelination | GMFG, MAG, SGMS1 | SMN1; SMN2 201/4885ALDH1A1 2402/4885KDM4E 2290/4885 |
| US-20190135776-A1 | THERAPEUTICS TARGETING TRUNCATED ADENOMATOUS POLYPOSIS COLI (APC) PROTEINS | APC, VHL, TP53 | SMN1; SMN2 4761/4885ALDH1A1 4595/4885KDM4E 2086/4885 |
| US-20160313302-A1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | SREBF1, SREBF2, EBPL | SMN1; SMN2 4880/4885ALDH1A1 4063/4885KDM4E 2393/4885 |
| US-20190269670-A1 | COMPOUNDS AND METHODS OF PROMOTING MYELINATION | GMFG, MAG, SGMS1 | SMN1; SMN2 201/4885ALDH1A1 2402/4885KDM4E 2290/4885 |
| US-10577344-B2 | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins | APC, VHL, TP53 | SMN1; SMN2 4761/4885ALDH1A1 4595/4885KDM4E 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.